Neumora Therapeutics, Inc. Common Stock NMRA · Stock Open Neumora Therapeutics, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Neumora Therapeutics, Inc. Common Stock Analysis (NMRA)
Is Neumora Therapeutics, Inc. Common Stock a good investment? Neumora Therapeutics, Inc. Common Stock (NMRA) is currently trading at 0.5660 USD. Market analysts have a consensus price target of 6.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Neumora Therapeutics, Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.65.
Investor FAQ
Does Neumora Therapeutics, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Neumora Therapeutics, Inc. Common Stock?
Neumora Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -1.23.
Company Profile
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Community Discussion